| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Lorbrena, Lorviqua in EU, fka PF-06463922 | |
| 3 | Generic | lorlatinib | |
| 4 | Indication | ALK+ NSCLC | |
| 5 | Clinical Trials | ||
| 6 | Phase III "CROWN" 1L vs. Xalkori ALK+ NSCLC | ||
| 7 | 64% DFS vs. 19% after 3 years |
| A | B | C | |
|---|---|---|---|
| 1 | Main | ||
| 2 | Brand | Lorbrena, Lorviqua in EU, fka PF-06463922 | |
| 3 | Generic | lorlatinib | |
| 4 | Indication | ALK+ NSCLC | |
| 5 | Clinical Trials | ||
| 6 | Phase III "CROWN" 1L vs. Xalkori ALK+ NSCLC | ||
| 7 | 64% DFS vs. 19% after 3 years |
Martin Shkreli